Endarterectomy Versus Stenting in Patients With Symptomatic Severe Carotid Stenosis - 2
Launched by CENTRE HOSPITALIER ST ANNE · Jul 7, 2025
Trial Information
Current as of August 19, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at two different treatments for people who have severe narrowing (called stenosis) in one of the main arteries in the neck, which can increase the risk of stroke. The two treatments being compared are carotid endarterectomy (CEA), a surgery to remove the blockage, and carotid artery stenting (CAS), which uses a small tube to open the artery without surgery. Researchers want to understand which treatment is better for preventing strokes in patients who recently had symptoms like a mini-stroke or stroke caused by this artery narrowing.
To join the study, participants need to be adults who had a recent stroke or mini-stroke affecting one side of the body or vision, and have a significant narrowing (between 50% and 99%) in the affected artery. People with serious other health problems, recent surgeries, or certain medical conditions may not be able to take part. If you join, you will receive either surgery or stenting based on guidelines, and doctors will follow your health over time to see how well the treatments work in preventing future strokes and how safe they are. This study is not recruiting yet, but it aims to help doctors make better decisions about treating carotid artery narrowing in people who have had symptoms.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient age 18 years or over
- • Hemispheric or retinal transient ischemic attack or a non-disabling stroke (or retinal infarct) within 15 days before enrolment
- • Stenosis of 50% to 99% in the symptomatic carotid artery (NASCET method) for whom revascularisation is decided according to guidelines
- Exclusion Criteria:
- • Patients unwilling or unable to participate in follow-up for whatever reason
- • Preexisting disability (Modified Rankin Score ≥ 3)
- • Nonatherosclerotic carotid disease
- • Severe tandem lesions
- • Previous revascularization of the symptomatic carotid stenosis
- • History of bleeding disorder
- • Unstable angina
- • Contraindication to dual antiplatelet therapy
- • Contraindication to MRI
- • Life expectancy of less than 2 years
- • Percutaneaous or surgical intervention within 30 days before or after the study procedure
- • Stenotic lesion on arterial workup appeared as not a factor in the selection
About Centre Hospitalier St Anne
Centre Hospitalier St. Anne is a leading healthcare institution dedicated to advancing medical knowledge and improving patient outcomes through innovative clinical research. With a strong emphasis on mental health and neurology, the center is committed to conducting high-quality clinical trials that adhere to rigorous ethical standards and regulatory guidelines. By fostering collaboration among multidisciplinary teams of experienced researchers and healthcare professionals, Centre Hospitalier St. Anne aims to contribute to the development of new therapies and treatment modalities, ultimately enhancing the quality of care for patients in both local and global contexts.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Paris, , France
Patients applied
Trial Officials
David Calvet, Professor
Study Director
GHU Sainte-Anne, PARIS
Benjamin GORY, Professor
Study Director
CHU NANCY
Antoine MILLON, Professor
Study Director
Hospices Civils de Lyon
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported